Brief: Simcere Pharmaceutical Says New Drug Application Of Rademikibart Was Accepted By China's NMPA
08/07/2025 05:21
July 8 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK: NEW DRUG APPLICATION (NDA) OF RADEMIKIBART WAS ACCEPTED BY CHINA'S NMPA Further company coverage: 2096.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660